Fernandez Camilo A, Potts Kaitlin, Bazzano Lydia A
Department of Epidemiology Tulane University School of Public Health and Tropical Medicine New Orleans Louisiana USA.
Center for Sport Tulane University School of Medicine New Orleans Louisiana USA.
Obes Sci Pract. 2021 Oct 15;8(3):299-307. doi: 10.1002/osp4.567. eCollection 2022 Jun.
Current guidelines call for peer-reviewed evidence of efficacy and safety for commercial weight loss programs to be recommended as options for those seeking to lose weight.
This study investigated the Ideal Protein (IP) system, a commercial weight loss program, compared to a guideline-based, low-calorie/low-fat (LCLF) dietary behavioral intervention on body weight and CVD risk factors in adults with obesity.
In this randomized, assessor-blinded, parallel-group trial, 192 participants with body mass index (BMI) ≥30 and ≤49 kg/m were assigned to either the IP Phase I diet or LFLC diet interventions. The IP Phase I is focused on lean protein and vegetables with avoidance of fruit and dairy, while the LFLC diet goals include <30% of daily energy from fat, <7% from saturated fat, 55% from carbohydrate, and an energy deficit of 500 kcal/day. The primary endpoint was change in body weight at 3 months. Secondary endpoints included change in waist circumference (WC), hip circumference (HC), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), fasting glucose (FG), systolic blood pressure (SBP) and diastolic blood pressure (DBP).
The mean ± SD of change in weight at 3 months was -9.6 ± 12.7 kg in the IP group as compared to -1.6 ± 27.2 kg in the LFLC group. The mean between-group difference in change at 3 months was -8.1 kg (95% confidence interval [CI] -16.6 to 0.6; = 0.05). Additional significant between-group differences included WC, HC, TC, and TG levels, all favoring the IP group. There were no serious adverse events during the intervention period.
The present findings demonstrate the efficacy and safety of the IP weight loss program as compared to a guideline-based LCLF dietary behavioral intervention among black and white adults with obesity and CVD risk factors, providing support for the effectiveness of the program.
当前指南要求商业减肥项目需有经过同行评审的疗效和安全性证据,才能被推荐为减肥者的选择。
本研究调查了理想蛋白质(IP)系统这一商业减肥项目,并将其与基于指南的低热量/低脂肪(LCLF)饮食行为干预对肥胖成年人的体重及心血管疾病风险因素的影响进行比较。
在这项随机、评估者盲法、平行组试验中,192名体重指数(BMI)≥30且≤49kg/m²的参与者被分配到IP第一阶段饮食或LFLC饮食干预组。IP第一阶段饮食侧重于瘦肉蛋白和蔬菜,避免食用水果和乳制品,而LFLC饮食目标包括每日脂肪供能<30%,饱和脂肪供能<7%,碳水化合物供能55%,且能量缺口为500千卡/天。主要终点是3个月时体重的变化。次要终点包括腰围(WC)、臀围(HC)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)、甘油三酯(TG)、空腹血糖(FG)、收缩压(SBP)和舒张压(DBP)的变化。
3个月时,IP组体重变化的均值±标准差为-9.6±12.7kg,而LFLC组为-1.6±27.2kg。3个月时组间变化的平均差异为-8.1kg(95%置信区间[CI]-16.6至0.6;P=0.05)。组间其他显著差异包括WCã€HCã€TC和TG水平,均有利于IP组。干预期间无严重不良事件。
目前的研究结果表明,与基于指南的LCLF饮食行为干预相比,IP减肥项目在有肥胖和心血管疾病风险因素的黑人和白人成年人中具有疗效和安全性,为该项目的有效性提供了支持。